[go: up one dir, main page]

MX2022011143A - Modulators of the integrated stress response pathway. - Google Patents

Modulators of the integrated stress response pathway.

Info

Publication number
MX2022011143A
MX2022011143A MX2022011143A MX2022011143A MX2022011143A MX 2022011143 A MX2022011143 A MX 2022011143A MX 2022011143 A MX2022011143 A MX 2022011143A MX 2022011143 A MX2022011143 A MX 2022011143A MX 2022011143 A MX2022011143 A MX 2022011143A
Authority
MX
Mexico
Prior art keywords
stress response
modulators
integrated stress
response pathway
compounds
Prior art date
Application number
MX2022011143A
Other languages
Spanish (es)
Inventor
Christopher John Brown
Daryl Simon Walter
James Lindsay Carr
Holly Victoria Atton
Scott Alexander Sadler
Jonathan Paul Shine
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of MX2022011143A publication Critical patent/MX2022011143A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Amplifiers (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra1, Ra2, Ra3, Ra4, Ra5, Ra6, A1 and A2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating and preventing of one or more diseases or disorders associated with integrated stress response.
MX2022011143A 2020-03-11 2021-03-10 Modulators of the integrated stress response pathway. MX2022011143A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20162329 2020-03-11
PCT/EP2021/056023 WO2021180774A1 (en) 2020-03-11 2021-03-10 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
MX2022011143A true MX2022011143A (en) 2022-10-13

Family

ID=69804610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011143A MX2022011143A (en) 2020-03-11 2021-03-10 Modulators of the integrated stress response pathway.

Country Status (11)

Country Link
US (1) US12441720B2 (en)
EP (1) EP4117780A1 (en)
JP (1) JP2023517944A (en)
KR (1) KR20220151635A (en)
CN (1) CN115190813B (en)
AU (1) AU2021236284A1 (en)
BR (1) BR112022014706A2 (en)
CA (1) CA3165813A1 (en)
IL (1) IL296220A (en)
MX (1) MX2022011143A (en)
WO (1) WO2021180774A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021366303A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
WO2022084447A1 (en) 2020-10-22 2022-04-28 Evotec International Gmbh Modulators of the integrated stress response pathway
WO2024109736A1 (en) * 2022-11-21 2024-05-30 深圳众格生物科技有限公司 Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
DE102023120315A1 (en) * 2023-07-31 2025-02-06 Rheinisch-Westfälische Technische Hochschule Aachen, abgekürzt RWTH Aachen, Körperschaft des öffentlichen Rechts Process for the preparation of pyrrolidone-substituted polyols

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270520T3 (en) 1997-06-12 2007-04-01 Aventis Pharma Limited IMIDAZOLIL-CYCLICAL ACETALS.
AU2014233520B2 (en) 2013-03-15 2019-02-21 The Regents Of The University Of California Modulators of the eIF2alpha pathway
TW201808888A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
TW201808903A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
TW201808914A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
TWI844006B (en) 2016-05-05 2024-06-01 美商嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
EP3468960B1 (en) 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
BR112018075615A2 (en) 2016-06-08 2019-07-02 Glaxosmithkline Ip Dev Ltd chemical compounds
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
BR112020000122A2 (en) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivatives of n- (3- (2- (4-chlorophenoxy) acetamido) bicyclo [1.1.1] pentan-1-yl) -2-cyclobutane-1-carboxamide and related compounds as inhibitors of atf4 for treatment against cancer and other diseases
WO2019008507A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
MX2020001352A (en) * 2017-08-09 2020-03-20 Denali Therapeutics Inc COMPOUNDS, COMPOSITIONS AND METHODS.
CN111201245B (en) * 2017-09-01 2024-04-05 戴纳立制药公司 Compounds, compositions, and methods
MX2020004557A (en) 2017-11-02 2020-10-05 Calico Life Sciences Llc Modulators of the integrated stress pathway.
AU2018360847B2 (en) 2017-11-02 2023-07-27 Abbvie Inc. Modulators of the integrated stress pathway
CA3080959A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37956A (en) 2017-11-02 2019-05-31 Abbvie Inc INTEGRATED STRESS ROAD MODULATORS
EP3704096A1 (en) 2017-11-02 2020-09-09 Calico Life Sciences LLC Modulators of the integrated stress pathway
BR112020008817B8 (en) 2017-11-02 2023-10-03 Abbvie Inc Integrated stress pathway modulating compounds
UY37958A (en) 2017-11-02 2019-05-31 Abbvie Inc INTEGRATED STRESS ROAD MODULATORS
UY37957A (en) 2017-11-02 2019-05-31 Abbvie Inc INTEGRATED STRESS ROAD MODULATORS
MX2020004556A (en) 2017-11-02 2020-10-05 Calico Life Sciences Llc Modulators of the integrated stress pathway.
MX2020006115A (en) 2017-12-13 2020-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway.
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
MX2020013269A (en) 2018-06-05 2021-02-18 Praxis Biotech LLC Inhibitors of integrated stress response pathway.
JP2021529814A (en) 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Chemical compound
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
TWI771621B (en) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 Prodrug modulators of the integrated stress pathway
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
CA3129609A1 (en) 2019-02-13 2020-08-20 Denali Therapeutics Inc. Eukaryotic initiation factor 2b modulators
SG11202107871UA (en) 2019-02-25 2021-08-30 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US20220177456A1 (en) 2019-03-06 2022-06-09 Denali Therapeutics Inc. Compounds, compositions and methods
CA3137212A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3137213A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
BR112021021754A2 (en) 2019-04-30 2022-02-08 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
PH12021552759A1 (en) 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
MX2021015210A (en) 2019-06-12 2022-01-18 Praxis Biotech LLC Inhibitors of integrated stress response pathway.
CN114466654A (en) 2019-06-12 2022-05-10 普拉西斯生物技术有限责任公司 Integrated stress response pathway modulators
BR112022012643A2 (en) 2020-01-28 2022-09-06 Evotec Int Gmbh INTEGRATED STRESS RESPONSE PATHWAY MODULATORS
AU2021366303A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
WO2022084447A1 (en) 2020-10-22 2022-04-28 Evotec International Gmbh Modulators of the integrated stress response pathway

Also Published As

Publication number Publication date
KR20220151635A (en) 2022-11-15
CN115190813B (en) 2024-10-15
CA3165813A1 (en) 2021-09-16
EP4117780A1 (en) 2023-01-18
IL296220A (en) 2022-11-01
JP2023517944A (en) 2023-04-27
US12441720B2 (en) 2025-10-14
BR112022014706A2 (en) 2022-10-11
US20230129907A1 (en) 2023-04-27
CN115190813A (en) 2022-10-14
AU2021236284A1 (en) 2022-08-18
WO2021180774A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2022011143A (en) Modulators of the integrated stress response pathway.
CL2021002772A1 (en) Modulators of the integrated stress response pathway
MX2022009243A (en) Modulators of the integrated stress response pathway.
MX2022008881A (en) Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology.
MX2025001619A (en) Pde4b inhibitor and use thereof
MX2022013482A (en) Compounds useful for inhibiting ret kinase.
EP4282486A3 (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
MX2021012904A (en) Modulators of the integrated stress response pathway.
NZ777871A (en) Small molecule modulators of il-17
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
CR20230066A (en) Heterocyclic glp-1 agonists
BR112014009717A2 (en) "2- (phenyl or pyrid-3-yl) aminopyrimidine derivatives, their uses, and pharmaceutical composition"
MX2021010106A (en) Inhibitors of integrated stress response pathway.
MX2023000521A (en) Pyridazinyl amino derivatives as alk5 inhibitors.
MX2018006225A (en) Pharmaceutical composition for treatment or prophylaxis of nash.
MX2022006086A (en) PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS.
BRPI0920605A8 (en) COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF HIV INFECTION OR FOR THE TREATMENT, PROPHYLAXIS, OR DELAY IN THE ONSET OR PROGRESSION OF AIDS IN A PATIENT IN NEED THEREOF.
MX2023006854A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof.
MX2025000291A (en) HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5â¿¢MTA AND USE THEREOF
MX2023003576A (en) Compound as akt kinase inhibitor.
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
MX2022011899A (en) SOLID DISPERSIONS OF AMORPHOUS 3, 4-DIPHENYL-4, 5-DIHYDRO- 1H-PYRAZOLE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF AS CANNABINOID CB<sub>1</sub> RECEPTOR INHIBITORS.
MX2022002839A (en) NEW TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND, METHOD OF PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND APPLICATION OF THE SAME.
MX2023004626A (en) Modulators of the integrated stress response pathway.
PH12021551035A1 (en) Pyrazoles as modulators of hemoglobin